Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Impact of prior therapies on selinexor, bortezomib and dex in R/R MM

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, shares the results of subgroup analyses from the Phase III BOSTON study (NCT03110562) of selinexor, bortezomib and dexamethasone (SVd) in relapsed/refractory multiple myeloma (R/R MM) patients, compared to bortezomib and dexamethasone alone (Vd). Selinexor, a selective inhibitor of nuclear export, causes myeloma cell apoptosis by blocking exportin-1. The BOSTON study found that the triplet combination significantly enhanced progression-free survival and response rates, compared to Vd. The impact of the number of lines of prior therapy (1-3), prior lenalidomide treatment, and prior treatment with proteasome inhibitors (PI) were all investigated as part of the study. The results found that the survival and response rate benefits seen in the SVd arm were independent of both the number of prior lines of therapy and previous lenalidomide exposure status. Adverse events were consistent across the subgroups. Additionally, an analysis of the impact of prior PI treatment found that there was a significant clinical benefit associated with SVd use, regardless of prior PI use. The benefits were, however, greater in PI-naïve patients. This study highlights the consistent benefit of SVd use for relapsed/refractory myeloma patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.